Background. Venous thromboembolism (VTE) is a common cardiovascular disease that seriously threatens human lives. Anticoagulant therapy is considered to be the cornerstone of VTE treatment. An increasing number of studies has been updated in the VTE anticoagulation field. However, no bibliometric analyses have assessed these publications comprehensively. Therefore, our study aimed to analyze the global status, hotspots, and trends of anticoagulant therapy for VTE. Methods. The relevant literature on VTE anticoagulation published between 2012 and 2021 was retrieved and collected from the Web of Science Core Collection database. VOSviewer, Cooccurrence Matrix Builder, gCLUTO, and some online visualization tools were adopted for bibliometric a...
Background Anticoagulation with low molecular weight heparin and vitamin K antagonists is the curren...
BACKGROUND: Management of venous thromboembolism (VTE), encompassing both deep vein thrombosis (DVT...
The Anticoagulation Length of Therapy and Risk of New Adverse Events In Venous Thromboembolism (ALTE...
Venous thromboembolism (VTE) is a common disorder associated with significant rates of morbidity and...
ABSTRACT The conjunction of atrial fibrillation (AF) and venous thromboembolism (VTE) is common in c...
Venous thromboembolism (VTE), the third most frequent acute cardiovascular syndrome, is associated w...
Background: The XALIA and XALIA-LEA prospective, noninterventional studies investigated the safety a...
BACKGROUND A global survey was conducted for the 10th anniversary of World Thrombosis Day to asse...
Background Best practice for prevention, diagnosis, and management of venous thromboembolism (VTE) i...
BACKGROUND: Pulmonary embolism and deep venous thrombosis, known as venous thromboembolism (VTE), ar...
Introduction: Low-molecular-weight heparin (LWMH) has been recommended as the preferred anticoagulan...
<p>Venous thromboembolism (VTE) management is rapidly evolving and staying up-to-date is challenging...
This article is a review of epidemiology, pathogenesis and treatment of venous thromboembolism (VTE)...
Abstract—Anticoagulant therapy is the cornerstone of treatment of venous thromboembolism (VTE). Such...
Worldwide, venous thromboembolism (VTE) is among the leading causes of death from cardiovascular dis...
Background Anticoagulation with low molecular weight heparin and vitamin K antagonists is the curren...
BACKGROUND: Management of venous thromboembolism (VTE), encompassing both deep vein thrombosis (DVT...
The Anticoagulation Length of Therapy and Risk of New Adverse Events In Venous Thromboembolism (ALTE...
Venous thromboembolism (VTE) is a common disorder associated with significant rates of morbidity and...
ABSTRACT The conjunction of atrial fibrillation (AF) and venous thromboembolism (VTE) is common in c...
Venous thromboembolism (VTE), the third most frequent acute cardiovascular syndrome, is associated w...
Background: The XALIA and XALIA-LEA prospective, noninterventional studies investigated the safety a...
BACKGROUND A global survey was conducted for the 10th anniversary of World Thrombosis Day to asse...
Background Best practice for prevention, diagnosis, and management of venous thromboembolism (VTE) i...
BACKGROUND: Pulmonary embolism and deep venous thrombosis, known as venous thromboembolism (VTE), ar...
Introduction: Low-molecular-weight heparin (LWMH) has been recommended as the preferred anticoagulan...
<p>Venous thromboembolism (VTE) management is rapidly evolving and staying up-to-date is challenging...
This article is a review of epidemiology, pathogenesis and treatment of venous thromboembolism (VTE)...
Abstract—Anticoagulant therapy is the cornerstone of treatment of venous thromboembolism (VTE). Such...
Worldwide, venous thromboembolism (VTE) is among the leading causes of death from cardiovascular dis...
Background Anticoagulation with low molecular weight heparin and vitamin K antagonists is the curren...
BACKGROUND: Management of venous thromboembolism (VTE), encompassing both deep vein thrombosis (DVT...
The Anticoagulation Length of Therapy and Risk of New Adverse Events In Venous Thromboembolism (ALTE...